Abstract
Background: A methodological problem arises when efficacy of clozapine is compared with other antipsychotic medication in double blind randomized studies. Due to the risk of leucopenia and agranulocytosis, patients in the clozapine condition need to have regular blood testing. The problem is that in order to maintain blinding, patients in the comparison conditions need to undergo blood testing as well and this can lead to underestimation of treatment acceptability and efficacy of the comparators.
Methods: A thought experiment considering all possible solutions for the methodological problem.
Results: We propose a special study design that preserves randomization and blinding while at the same time prevents underestimation of the effect in the comparator treatments. In addition, the necessity for blood testing is limited to only a small number of patients who receive comparative treatments. The design involves initial randomization to a sub‐study including clozapine and a small comparator arm or to a sub‐study that includes only comparator arms. Blood testing is only necessary in the first sub‐study.
Discussion: Limitations of the proposed design are discussed. It is noted that this study design may offer a solution to similar situations where blood testing or other types of monitoring (e.g. as with lithium) is required in one but not in all of the treatment arms of a double blind randomized study. Copyright © 2009 John Wiley & Sons, Ltd.
Keywords: methodology, Clozapine, agranulocytosis, double blind, clinical trials
Full Text
The Full Text of this article is available as a PDF (106.5 KB).
REFERENCES
- Afshar H., Roohafza H., Mousavi G., Golchin S., Toghianifar N., Sadeghi M., Talaei M. (2008) Topiramate add‐on treatment in schizophrenia: a randomised, double‐blind, placebo‐ controlled clinical trial. Journal of Psychopharmacology, 23; 157–162. [DOI] [PubMed] [Google Scholar]
- Buckley P., Thompson P.A., Way L., Meltzer H.Y. (1994) Substance abuse and clozapine treatment. Journal of Clinical Psychiatry, 55(Suppl. B), 114–116. [PubMed] [Google Scholar]
- Green A.I., Burgess E.S., Dawson R., Zimmet S.V., Strous R.D. (2003) Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophrenia Research, 60, 81–85, DOI: 10.1016/S0920‐9964(02)00231‐1 [DOI] [PubMed] [Google Scholar]
- Harrison P.J. (2008) Metabotropic glutamate receptor agonists for schizophrenia. British Journal of Psychiatry, 192, 86–87, DOI: 10.1192/bjp.bp.107.045088 [DOI] [PubMed] [Google Scholar]
- Hashimoto K. (2006) Glycine transporter inhibitors as therapeutic agents for schizophrenia. Recent Patents on CNS Drug Discovery, 1, 43–53. [DOI] [PubMed] [Google Scholar]
- Kelly D.L., Conley R.R., Richardson C.M., Tamminga C.A., Carpenter W.T. Jr. (2003a) Adverse effects and laboratory parameters of high‐dose olanzapine vs. clozapine in treatment‐resistant schizophrenia. Annals of Clinical Psychiatry, 15: 181–186, DOI: 10.1023/B:ACLI.0000008171.90644.f8 [DOI] [PubMed] [Google Scholar]
- Kelly D.L., Gale E.A., Conley R.R. (2003b) Clozapine treatment in patients with prior substance abuse. Canadian Journal of Psychiatry, 48, 111–114. [DOI] [PubMed] [Google Scholar]
- Meltzer H.Y., Bobo W.V., Roy A., Jayathilake K., Chen Y., Ertugrul A., Anil Yağcioğlu A.E., Small J.G. (2008) A randomized, double‐blind comparison of clozapine and high‐dose olanzapine in treatment‐resistant patients with schizophrenia. Journal of Clinical Psychiatry, 69, 274–285. [DOI] [PubMed] [Google Scholar]
- Snyder E.M., Murphy M.R. (2008) Schizophrenia therapy: beyond atypical antipsychotics. Nature Reviews Drug Discovery, 7, 471–472, DOI: 10.1038/nrd2571 [DOI] [PubMed] [Google Scholar]
- Tollefson G.D., Birkett M.A., Kiesler G.M., Wood A.J. (2001) Lilly resistant schizophrenia study group. Double‐blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biological Psychiatry, 49, 52–63, DOI: 10.1016/S0006‐3223(00)01026‐X [DOI] [PubMed] [Google Scholar]
- Volavka J., Czobor P., Sheitman B., Lindenmayer J.P., Citrome L., McEvoy J.P., Cooper T.B., Chakos M., Lieberman J.A. (2002) Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. American Journal of Psychiatry, 159, 255–262. [DOI] [PubMed] [Google Scholar]
- Zimmet S.V., Strous R.D., Burgess E.S., Kohnstamm S., Green A.I. (2000) Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey. Journal of Clinical Psychopharmacology, 20, 94–98. [DOI] [PubMed] [Google Scholar]